PD-L1 expression and prediction of response to immune modulators in non-small cell lung cancer; reasons for its fragility and strategies to reduce it

Alexander Haragan
Abstract Introduction Anti-PD-1/PD-L1 immunomodulatory (IM) therapy has revolutionised the treatment of non-small cell lung cancer (NSCLC). The only ‘biomarker’ currently-validated for predicting response of these tumours to IM therapy is the extent of PD-L1 expression as detected by immunohistochemistry (IHC). Despite the overall success of this therapy in patients with NSCLC, PD-L1 expression is an imperfect predictor, some patients with tumours displaying low expression responding strongly, and some with high expression not at all. The...
This data repository is not currently reporting usage information. For information on how your repository can submit usage information, please see our documentation.